Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BIIB059

Biogen Idec building

Biogen rises on more positive data for Alzheimer’s candidate

Early-stage trial throws lifeline to proponents of beleaguered amyloid hypothesis

Living with Crohn’s disease: a patient perspective

Account Executive Victoria Morton explores what it’s like to live with Crohn’s disease as a young person, and investigates what’s being done to tackle the gaps in treatment options for...

Blue Latitude Health

Eli Lilly HQ

Lilly sinks as solanezumab fails again in Alzheimer’s

Amyloid-targeting drug showed no significant evidence of slow in cognitive decline

Research Partnership launches new patient report – Living with Lupus (SLE)

Living with Lupus (SLE) is a quantitative study conducted online amongst patients in the US and European markets. The report will consist of 30-minute face to face interviews with a...

Research Partnership

- PMLiVE

Opening up innovation

Paul-Peter Tak on GlaxoSmithKline’s R&D strategy and the pivotal role of immunology

Roche Basel Switzerland

Roche snags pair of FDA breakthrough designations

Accelerates approval process for NSCLC treatment Alecensa and immunotherapy Actemra

- PMLiVE

Biogen launches Remicade biosimilar in the UK

Flixabi provides another low-cost alternative to J&J’s biggest-selling drug

- PMLiVE

Lupus trial hailed as a success despite patient deaths

Phase IIb trial of Aurinia Pharmaceuticals’ voclosporin met its objective

Biogen Idec building

Eisai and Biogen plan phase III trials for Alzheimer’s drug

BACE inhibitor E2609 may offer new treatment option

Biogen Idec building

Biogen buys into Ionis’ nusinersen after positive phase III trial

Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months” 

- PMLiVE

Pfizer buys gene therapy specialist Bamboo

Expands pipeline with Duchenne muscular dystrophy candidate in deal worth $700m

Biogen Idec building

Biogen’s CEO Scangos to step down

Departure comes as multiple sclerosis drug Tecfidera achieves improved sales growth

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links